^
    1m
    Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer (clinicaltrials.gov)
    P1/2, N=186, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • HER-2 expression
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    1m
    ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (clinicaltrials.gov)
    P3, N=402, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Mar 2030 --> May 2031 | Trial primary completion date: Jun 2027 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt)
    1m
    Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies (clinicaltrials.gov)
    P1/2, N=51, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD4 (CD4 Molecule)
    |
    PD-L1 negative
    |
    bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC
    2ms
    Mapping the research landscape of myelodysplastic syndromes: a scientometric analysis (2014-2025). (PubMed, Clin Exp Med)
    Thematic analysis identified research hotspots across multiple dimensions, including 5q deletion, trisomy 8, germline predisposition, TP53 mutation, clonal hematopoiesis, inflammation, venetoclax, luspatercept, targeted therapy, immunotherapy, pediatric population, VEXAS syndrome, IPSS-R, relapse, prognosis, overall survival, and artificial intelligence. Future advances are expected to rely on multi-ethnic cohort building, mechanism exploration, combined treatment regimen optimization and novel drug development. Strengthening multidisciplinary collaboration is anticipated to facilitate clinical translation and foster more precise, equitable and clinically practical management of MDS globally.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • Reblozyl (luspatercept-aamt)
    2ms
    SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=112, Not yet recruiting, Sinocelltech Ltd.
    New P1/2 trial
    2ms
    Luspatercept for CIA in AML (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Guangdong Second Provincial General Hospital
    New P1/2 trial
    |
    Reblozyl (luspatercept-aamt)
    2ms
    From M7824 to SHR-1701: lessons for dual PD-L1/TGF-β targeting. (PubMed, J Immunother Cancer)
    We highlight that TGF-β-driven immune suppression and immune exclusion are often spatially organized within stromal niches, vary across indications, and are not always the dominant barrier even when PD-L1 is expressed. SHR-1701's approval provides proof of principle in a defined context and supports mechanism-aligned development using biomarker-driven selection, rational combinations and sequencing, and pharmacodynamic endpoints that directly test these assumptions.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression
    |
    bintrafusp alfa (M7824) • retlirafusp alfa (SHR-1701)
    2ms
    SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=410, Recruiting, Sinocelltech Ltd.
    New P2/3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed
    2ms
    A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jun 2026 --> Jun 2028 | Trial completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt)
    2ms
    A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
    New P1 trial
    2ms
    Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma. (PubMed, Cancer Immunol Immunother)
    Although the primary endpoint was not met, BA showed a manageable safety profile and a subset of patients derived clinical benefit with prolonged stable disease, including one patient with a complete metabolic response. This first clinical trial of systemic therapy in R/M ONB serves as proof of clinical trials feasibility in this setting and supports further investigation of combinatorial immunotherapy strategies in this patient population. Trial registration ClinicalTrials.gov Identifier: NCT05012098, https://clinicaltrials.gov/ct2/show/NCT05012098. Registered 18 August 2021.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    bintrafusp alfa (M7824)
    2ms
    SOFAPI: Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH (clinicaltrials.gov)
    P1/2, N=15, Not yet recruiting, University Hospital, Brest | Trial completion date: Dec 2028 --> Jan 2028 | Initiation date: Jan 2026 --> Jul 2026 | Trial primary completion date: Jan 2027 --> Jan 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Winrevair (sotatercept-csrk)